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Abstract 
Background: In addition to controlled post-translational modifications proteins can be modified with highly reac-
tive compounds. Usually this leads to a compromised functionality of the protein. Methylglyoxal is one of the most 
common agents that attack arginine residues. Methylglyoxal is also regarded as a pro-oxidant that affects cellular 
redox homeostasis by contributing to the formation of reactive oxygen species. Antioxidant enzymes like catalase are 
required to protect the cell from oxidative damage. These enzymes are also targets for methylglyoxal-mediated modi-
fication which could severely affect their catalytic activity in breaking down reactive oxygen species to less reactive or 
inert compounds.
Results: Here, bovine liver catalase was incubated with high levels of methylglyoxal to induce its glycation. This treat-
ment did not lead to a pronounced reduction of enzymatic activity. Subsequently methylglyoxal-mediated arginine 
modifications (hydroimidazolone and dihydroxyimidazolidine) were quantitatively analysed by sensitive nano high 
performance liquid chromatography/electron spray ionisation/tandem mass spectrometry. Whereas several arginine 
residues displayed low to moderate levels of glycation (e.g., Arg93, Arg365, Arg444) Arg354 in the active centre of 
catalase was never found to be modified.
Conclusions: Bovine liver catalase is able to tolerate very high levels of the modifying α-oxoaldehyde methylglyoxal 
so that its essential enzymatic function is not impaired.
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Modification
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Background
Proteins can be covalently modified by a staggering vari-
ety of chemical moieties. Some of these modifications 
lead to changes in the functional life time of a protein 
(e.g., polyubiquitination as a prerequisite for degradation 
of the target protein by the 26 s proteasome, SUMOyla-
tion for enhancing protein stability, etc.). Other modifi-
cations more or less directly influence enzymatic activity 
(e.g., phosphorylation and acetylation to name but a few). 
The aforementioned examples have in common that 
the cell controls if or if not a given post-translational 
modification occurs. In contrast, modifications that 
occur non-enzymatically are often detrimental to pro-
tein function (although there are exceptions from this 
rule) [1]. Among these are reactions of highly reactive 
low molecular weight compounds (e.g., reactive oxygen 
species, reducing sugars, etc.) with specific amino acids 
[2, 3]. Here the reaction of methylglyoxal with arginine 
(and to a lesser extent lysine) residues will be briefly 
described. Methylglyoxal is formed as a toxic by-product 
of the catabolic breakdown of d-glucose (glycolysis) [4]. 
Usually the cellular level of this α-oxoaldehyde is rather 
low (approx. 2–4 µM in cells and tissues [5–7]). However, 
in pathological hyperglycaemic conditions like diabe-
tes it can be elevated to critical levels and subsequently 
severely impair cellular functions [8–10]. After the 
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initial binding of methylglyoxal to the protein hydroimi-
dazolone MG-H1 and dihydroxyimidazolidine (DHI) [11] 
intermediates are formed that can be further rearranged 
to give rise to so-called ‘advanced glycation end products’ 
(AGEs) [12]. The deleterious properties of AGEs are well 
documented and many efforts are directed to counter-
act their formation (reviewed in [13]). Methylglyoxal-
mediated toxicity is intimately linked to conditions of 
oxidative stress (reviewed in [14]). These two damaging 
situations amplify each other and unsurprisingly cause 
profound obstacles for cellular function and survival. 
Methylglyoxal is known to affect the ability of a cell to 
cope with oxidative stress by modifying antioxidative 
proteins like catalase [15, 16], ascorbate peroxidase [17], 
superoxide dismutase [16], glutathione peroxidase [18] 
and albumin [19] which are required to keep levels of 
reactive oxygen species at (low) physiological concentra-
tions. Catalase isolated from bovine liver is a protein of 
240 kDa (mass of the functional tetramer). Heme serves 
as a prosthetic group while NADPH can be bound as a 
cofactor. The former is required for the catalytic break-
down of the reactive oxygen species hydrogen peroxide 
to water and molecular oxygen [20] whereas the latter 
seems to protect the enzyme from off-pathway oxidized 
enzyme states [21, 22]. An amino acid residue of critical 
importance is Arginine354 (Arg354) which constitutes a 
‘charge relay’ along with His218 and Asp348 to stabilize 
the electrostatic field generated by different iron oxida-
tion states within the active centre of the enzyme [22]. It 
has been speculated that the modification of this arginine 
by methylglyoxal-mediated glycation could lead to an 
altered catalase activity [15].
To test whether Arg354 is a target for glycation by 
methylglyoxal experimentally an in  vitro glycation pro-
cedure was developed. Unlike previous protocols this 
procedure uses relatively high concentrations of methyl-
glyoxal (160 mM) for short periods of time (2 h). In order 
to identify whether Arg354 is glycated or not nanoHPLC-
ESI–MS/MS was performed. In addition to Arg354 other 
arginine residues involved in the formation of catalase 
tetramers and in NADPH binding were investigated. The 
data presented here suggest that Arg354 is protected 
from methylglyoxal-mediated glycation. This is in line 
with measurements of catalase activity demonstrating 
that methylglyoxal treatment has no significant effect on 
the catalytic activity of catalase. However, other arginines 
(Arg93, Arg263, Arg365 and Arg444) display low to 
medium levels of MG-H1 and DHI formation indicating 
that glycation occurred at these positions. In summary, 
bovine liver catalase is able to maintain its activity under 
experimental conditions involving high levels of methyl-
glyoxal that lead to glycation of several arginine residues 
but not of Arg354 which is located in the active centre of 
the enzyme. These findings demonstrate the importance 
of this antioxidative enzyme in keeping levels of hydro-
gen peroxide low even under challenging conditions.
Results
Effects of methylglyoxal treatment on bovine liver catalase 
activity
The effect of methylglyoxal on the enzymatic activity of 
bovine liver catalase has been investigated in a previ-
ous study [15]. In the present work, an altered protocol 
for in  vitro glycation of this enzyme [higher methylgly-
oxal concentrations (160 mM vs. up to 5 mM) for shorter 
times (2 h) instead of at least 5 h] has been applied. The 
aim of these experiments was not to emulate in vivo lev-
els of methylglyoxal but to determine whether different 
arginine residues of bovine liver catalase display quanti-
tative differences in their tendency to be subject to glyca-
tion. In order to determine catalase activity under these 
experimental glycation conditions a spectrophotometric 
assay (see “Methods” section) was used.
A catalase-containing solution that has not been 
treated with methylglyoxal is capable to degrade half of 
the hydrogen peroxide present in the assay buffer at time 
0 within approx. 45 s (Fig. 1). When the purified catalase 
enzyme is pre-incubated in buffer containing 160  mM 
methylglyoxal for 2  h before being diluted into assay 
buffer no clear differences of enzyme activity compared 
to the untreated control are measured. Catalase activity is 
maintained at later time points of the assay (60, 75, 90 s) 
although it tends to be slightly reduced compared to the 
untreated control. These data show that bovine liver cata-
lase is able to maintain its activity even in the presence of 
high concentrations of methylglyoxal.
Analysis of methylglyoxal‑mediated protein modifications
The question arises if and to what extent relevant argi-
nine residues in bovine liver catalase have been subjected 
to glycation during the in vitro glycation experiment. A 
highly sensitive method (nanoHPLC-ESI–MS/MS, see 
“Methods” section) has been utilized to analyse cata-
lase peptide ions for modifications of arginine residues. 
The total ion currents and extracted ion currents of the 
mass spectra corresponding to the modifications MG-H1 
and DHI have been compiled in Additional file  1: Fig-
ure S1. The following functionally relevant arginine 
residues [22] were quantitatively analysed for modifica-
tions: Arg66, Arg68, Arg263, Arg365 are involved in the 
formation of the catalase tetramer interface, Arg354 is 
involved in binding of the heme prosthetic group in the 
active centre of the enzyme, Arg203 contributes to bind-
ing of the cofactor NADPH while Arg93 and Arg444 have 
no documented role in catalase function and serve as 
“out-groupers”.
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Both Arg93 and Arg444 display the highest levels of 
glycation modifications (Table 1) (Arg93: 13.2 % of pep-
tide ions bear the MG-H1 modification and 10.8  % are 
DHI-modified; Arg444: 6.3  % MG-H1 and 7.3  % DHI). 
These arginine residues seem to be highly accessible to 
the reaction with methylglyoxal (see “Discussion” sec-
tion). Furthermore, this result shows that MG-H1 and 
DHI modifications occur using the glycation protocol 
used in this study (“glycation positive control”). It was 
not possible to obtain peptide ions which solely contain 
Arg203 and no other arginine (Table 1). The peptide ion 
that was analysed contains a further arginine residue 
(Arg210). Therefore the detected modifications (MG-H1: 
2.7 %, DHI: 1.0 %) cannot be solely attributed to Arg203. 
However, it is clear that the level of modification is much 
smaller compared to the out-groupers. The three argi-
nine residues involved in the formation of the tetramer 
interaction surface all display low levels of modification 
Fig. 1 Determination of catalase activity in the absence or presence of methylglyoxal. Mean values of three different measurements are shown in 
the diagram. Error bars denote the standard deviation of the mean value. MG methylglyoxal (160 mM)
Table 1 Methylglyoxal-dependent modifications of catalase
Arginine residues of interest are printed in italic letters
m/z mass to charge ratio, nm non-modified catalase peptide ion, nd not detected
Sequence Position Modification m/z Peak area % modified
F.DRERIPERVVH.A 65–75 nm 469.260 141,239,376
MG-H1 487.263 1,972,739 1.4
DHI 493.267 2,816,325 1.9
F.GYFEVTHDITRY.S 83–94 nm 750.860 35,923,631
MG-H1 777.865 6,243,848 13.2
DHI 786.870 5,107,276 10.8
F.SDRGIPDGHRHM.N 201–212 nm 459.886 36,013,455
MG-H1 477.889 1,015,794 2.7
DHI 483.893 1,049,274 1.0
L.AHEDPDYGLRDLF.N 254–266 nm 774.360 104,144,627
MG-H1 801.365 140,068 0.1
DHI 810.370 393,409 0.4
M.LQGRLF.A 351–356 nm 367.221 68,678,448
MG-H1 394.226 nd 0.0
DHI 403.231 nd 0.0
H.RHRLGPNYLQIPVNCPY.R 363–379 nm 699.698 13,777,078
MG-H1 717.702 225,543 1.6
DHI 723.705 130,193 0.9
F.NSANDDNVTQVRTF.Y 433–446 nm 790.868 194,414,574
MG-H1 817.874 14,193,861 6.3
DHI 826.879 16,307,423 7.3
Page 4 of 6Scheckhuber  BMC Res Notes  (2015) 8:830 
(Arg66 + Arg68, MG-H1: 1.4  %; DHI: 1.9  %; Arg263, 
MG-H1: 0.1 %; DHI: 0.4 %; Arg365, MG-H1: 1.6 %; DHI: 
0.9 %) (Table 1). Strikingly, Arg354 located in the active 
centre of catalase displays no modifications (neither 
MG-H1 nor DHI) at all (Table 1). In summary these data 
indicate that bovine liver catalase is able to maintain 
integrity of its catalytic core even in the presence of very 
high levels of methylglyoxal.
Discussion
Although harsh glycation conditions were used for the 
treatment of bovine liver catalase arginine residue 354 in 
the catalytic centre of this enzyme was not found to be 
modified by methylglyoxal. Bovine liver catalase activity 
can indeed be maintained under these conditions which 
is in line with a previous study that used much lower 
amounts of glycating agents [15]. Arg354 is situated in 
a deep pocket formed by a β-barrel structure with few 
channels providing access to the heme. This arginine resi-
due is involved in the catalytic mechanism of breaking 
down the catalase substrate, hydrogen peroxide, by cleav-
age of the peroxide bond. This leads to the formation of 
an intermediate compound with subsequent neutrali-
sation of Arg354 [22]. The data presented in this study 
suggest that the reactive methylglyoxal is not able to 
penetrate this deep into the active centre of the enzyme. 
By contrast, Arg93 and Arg444 show the highest level of 
methylglyoxal-mediated modification. This finding corre-
lates well with the fact that these residues are located on 
the surface of the protein according to the crystal struc-
ture of bovine liver catalase as determined by electron 
crystallography of thin 3D crystals (Protein Data Bank 
Europe identifier 3j7u) [23] and thus accessible to meth-
ylglyoxal. Arg66, Arg68, Arg203, Arg210, Arg263 and 
Arg365 are neither buried deep in hydrophobic pockets 
nor directly located on the surface of catalase and display 
low to moderate levels of glycation.
Certainly it is important that key antioxidative enzymes 
like catalase are protected from deleterious glycation 
reactions because it is well documented that methylg-
lyoxal can contribute to oxidative stress in various cell 
types (reviewed in [14]). For instance, methylglyoxal was 
found to elevate the generation of hydrogen peroxide 
and the pro-oxidant peroxynitrite in rat aortic vascular 
smooth muscle cells [24]. Not only hydrogen peroxide 
levels were increased by methylglyoxal in these cells but 
also other reactive oxygen species like superoxide anions 
were present in elevated concentrations. Methylglyoxal 
was also found to deplete cellular stores of the antioxi-
dant molecule glutathione (GSH) which is of high impor-
tance for maintenance of the cellular redox potential [25, 
26]. There are many more examples how methylglyoxal 
negatively influences the cellular redox balance (reviewed 
in [14]). In summary, methylglyoxal can be classified as 
a pro-oxidant. Without the defensive function of anti-
oxidative enzymes like catalase organisms would be ren-
dered even more susceptible to oxidative stress and its 
deleterious consequences for health and viability. There-
fore it seems plausible that the catalytic centre of catalase 
(specifically Arg354) is protected from methylglyoxal-
mediated glycation. The activity of other antioxidant 
enzymes is also quite resistant to modification by glycat-
ing agents (e.g., incubation of superoxide dismutase with 
50 mM fructose for 3 days led to >80 % remaining enzy-
matic activity [16]). By contrast, ascorbate peroxidase 
from Nicotiana tabacum displays activity loss when this 
protein is subject to glycation [17]. This is probably due 
to an increased km value for ascorbate due to the glyca-
tion [17]. In another study, glutathione peroxidase activ-
ity was found to be severely affected by treatment with 
5  mM methylglyoxal for 3  h [18]. These results suggest 
that peroxidases are more readily affected by methylgly-
oxal compared to catalase and superoxide dismutase.
Methods
Catalase glycation procedure/catalase activity assay
Catalase (cat. no. C1345, catalase from bovine liver, Sigma–
Aldrich, Taufkirchen, Germany) stock solution (10  mg/
ml) was prepared in 50  mM potassium phosphate buffer 
(pH 7.0) and stored at 4  °C. Before beginning the assays, 
the stock solution was diluted 1/100 in 50  mM potas-
sium phosphate buffer (pH 7.0) containing no (control) or 
160  mM methylglyoxal (cat. no. M0252, Sigma-Aldrich, 
Taufkirchen, Germany) for 2 h at room temperature. 100 µl 
of this solution was mixed with 2.9 ml assay buffer (0.075 % 
[v/v] hydrogen peroxide in 50  mM potassium phosphate 
buffer [pH 7.0]). Measurements were made exactly for 
90  s after enzyme addition in 15  s intervals at 240 nm in 
a spectrophotometer (NanoPhotometer, Implen, Munich, 
Germany). As a negative control, 0.075  % (v/v) hydrogen 
peroxide in 50  mM potassium phosphate buffer (pH 7.0) 
was incubated with 160 mM methylglyoxal without added 
catalase. There was no change in absorbance at 240 nm (i.e., 
it remained constant at approx. A240nm 0.93). This control 
demonstrates that hydrogen peroxide and methylglyoxal do 
not react non-enzymatically with each other.
Determination of methylglyoxal‑mediated arginine 
modifications of catalase
Catalase samples treated with methylglyoxal as described 
above and untreated controls were purified by using 
Amicon Ultra-0.5 30  K centrifugal filter devices (Merck 
Millipore, Schwalbach, Germany). The washing step was 
conducted with pure water. The purified catalase solution 
(ca. 50 µl) was added to 50 µl 100 mM potassium phos-
phate buffer, pH 6.9.
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Characterisation of arginine modifications in con-
trol and methylglyoxal-treated catalase via nanoHPLC-
ESI–MS/MS was performed by Proteome Factory AG 
(Berlin, Germany). Dry protein samples were dissolved 
in 8  M urea containing 25  mM TCEP [Tris(2-carboxy-
ethyl)phosphine] and incubated for 30 min at room tem-
perature. Alkylation was carried out for an additional 
30  min by adding 50  mM iodoacetamide (final concen-
tration). The alkylated protein samples were subject to 
proteolysis over-night using chymotrypsin 1:50 (w/w) 
(Sigma, Germany). The acidified peptides were analysed 
by nanoHPLC-ESI–MS/MS. The liquid chromatography 
mass spectrometry system consisted of an Agilent 1100 
nanoHPLC (Agilent, Waldbronn, Germany), PicoTip 
electrospray emitter (New Objective, Woburn, MA) 
and an Orbitrap XL or LTQ-FT Ultra mass spectrom-
eter (ThermoFisher Scientific, Bremen, Germany). Pep-
tides were first trapped and desalted on the enrichment 
column (Zorbax 300SB-C18, 0.3  ×  5  mm, Agilent) for 
5 min (solvent: 2.5 % acetonitrile/0.5 % formic acid), then 
separated on a Zorbax 300SB-C18, 75 µm × 150 mm col-
umn (Agilent) using a linear gradient from 10 to 32 % B 
(solvent A: 5 % acetonitrile in water, solvent B: acetoni-
trile, both with 0.1 % formic acid). Ions of interest were 
subjected to MS/MS according to the expected charge 
state distribution of peptide ions. Proteins were identi-
fied by database search against the NCBInr protein data-
base (National Center for Biotechnology Information, 
Bethesda, USA) using MS/MS ion search of the Mascot 
search engine (Matrix Science, London, England) allow-
ing detection of the glycation modifications at arginine 
residues dihydroxyimidazolidine (DHI) (peptide mass 
shift: +72  Da) and hydroimidazolone MG-H1 (peptide 
mass shift: +54  Da), respectively. Selected ion signals 
were extracted using Qualbrowser (ThermoFisher Scien-
tific, Bremen, Germany).
Calculation of methylglyoxal‑modified peptide ions
The peptide ions that were detected with the highest 
abundance were selected for calculating the percentage of 
methylglyoxal-mediated MG-H1 and DHI modifications. 
The areas of peaks of interest in the chromatograms were 
determined by integration. Calculations for % modifica-
tions of peptide ions were performed with the following 
equations:
ADHI and AMGH1 correspond to the areas of the inte-










AMGH1 + ADHI + ANM
)
× 100%
ions, respectively. ANM is the area of the integrated peak 
of the non-modified peptide ion.
Abbreviations
AGE: advanced glycation end product; DHI: dihydroxyimidazolidine; MG-H1: 
hydroimidazolone.
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